10435-57-1 Usage
General Description
5-Cyanosalicylic acid is a chemical compound with the molecular formula C8H5NO4. It is a derivative of salicylic acid, containing a cyano group (-CN) at the 5-position of the benzene ring. 5-Cyanosalicylic acid is commonly used as a reagent in the synthesis of organic compounds and as a starting material for the production of other chemicals. It has also been studied for its potential pharmaceutical applications, particularly for its anti-inflammatory and antioxidant properties. Additionally, 5-Cyanosalicylic acid has been investigated for its use in analytical chemistry as a reagent for the detection and quantification of various metal ions in solution. Overall, 5-Cyanosalicylic acid has a range of practical and potential applications in industry, pharmaceuticals, and research.
Check Digit Verification of cas no
The CAS Registry Mumber 10435-57-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,4,3 and 5 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 10435-57:
(7*1)+(6*0)+(5*4)+(4*3)+(3*5)+(2*5)+(1*7)=71
71 % 10 = 1
So 10435-57-1 is a valid CAS Registry Number.
10435-57-1Relevant articles and documents
Synthesis, evaluation and docking studies of some 4-thiazolone derivatives as effective lipoxygenase inhibitors
Shrivastava, Sushant Kumar,Patel, Brijesh K.,Tripathi, Prabhash Nath,Srivastava, Pavan,Sharma, Piyoosh,Tripathi, Avanish,Seth, Ankit,Tripathi, Manish Kumar
, p. 2769 - 2783 (2018)
Some promising 4-thiazolone derivatives as lipoxygenase inhibitors were designed, synthesized, characterized and evaluated for anti-inflammatory activity and respective ulcerogenic liabilities. Compounds (1b, 1e, 3b, and 3e) exhibited considerable in vivo
INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS
-
Page/Page column 161, (2021/01/29)
The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS
-
Paragraph 0649; 0652, (2021/12/03)
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein.